Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1014-25-1 | MDL No. : | MFCD00813220 |
Formula : | C9H9N3OS | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | UJBCFMCQLVRXBQ-UHFFFAOYSA-N |
M.W : | 207.25 | Pubchem ID : | 692882 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.11 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 56.24 |
TPSA : | 89.27 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.39 cm/s |
Log Po/w (iLOGP) : | 1.84 |
Log Po/w (XLOGP3) : | 1.65 |
Log Po/w (WLOGP) : | 1.8 |
Log Po/w (MLOGP) : | 0.94 |
Log Po/w (SILICOS-IT) : | 2.41 |
Consensus Log Po/w : | 1.73 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.61 |
Solubility : | 0.504 mg/ml ; 0.00243 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.14 |
Solubility : | 0.151 mg/ml ; 0.000728 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.21 |
Solubility : | 0.127 mg/ml ; 0.000611 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.46 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
86.4% | at 80℃; for 2.5 h; | General procedure: A stirring mixture of benzoic acid (0.2442 g, 2.0 mmol), thiosemicarbazide (0.1823 g, 2.0 mmol) and POCl3 (1.2 ml) was heated at 80 oC for 2.5 h. After cooling down to room temperature, water (2.5 mL) was added. The reaction mixture was refluxed for 4 h. After cooling, the mixture was basified to pH 8 by the dropwise addition of 40percent NaOH solution under stirring. The precipitate was filtered and recrystallized from ethanol to yield 0.3130 g of the target compound 1a as a white solid ,Yield: 88.3percent. |
82% | Stage #1: at 75℃; for 0.5 h; Stage #2: for 4 h; Reflux |
General procedure: 5.1.1 5-(4-Morpholinophenyl)-1,3,4-thiadiazol-2-amine (59) A mixture of 4-morpholinobenzoic acid (5.18 g, 25 mmol) and N-aminothiourea (2.28 g, 25 mmol) in POCl3 (7 ml) was stirred vigorously at 75 °C for 0.5 h. After addition of H2O (30 ml), the reaction mixture was heated under reflux for 4 h and basified to pH 8 by 50percent NaOH solution. The mixture was filtered and the filter cake was recrystallized from ethanol to yield 3.90 g of compound 59 as a yellow crystal. Yield: 59percent; The synthetic procedures of compounds 60–81 were the same as that described above. 5.1.1.2 5-(4-Methoxyphenyl)-1,3,4-thiadiazol-2-amine (61) Yield: 82percent, mp: 219-220 °C (EtOH). ESI-MS m/z: 208.2 [M+H]+; 1H NMR (DMSO-d6) δ 3.80 (s, 3H), 7.01-7.03 (m, 2H), 7.23 (s, 2H), 7.67-7.69 (m, 2H). |
81.3% | at 75℃; for 0.5 h; | General procedure: A stirring mixture of benzoic acid (7.32 g, 60 mmol), N-aminothiourea(6.38 g, 70 mmol) and POCl3 (20 ml) washeated at 75 °C for 0.5 h. After cooling down to room temperature,water was added. The reaction mixture was refluxedfor 4 h. After cooling, the mixture was basified to pH8 by the drop-wise addition of 50percent NaOH solution understirring. The precipitate was filtered and re-crystallized from ethanol |
76.09% | at 85℃; for 10 h; | p-Anisic acid (3.04 g, 20 mmol) and thiosemicarbazide (1.82 g,20 mmol) were dissolved in 30 mL of phosphorus oxychloride, thereaction mixture was refluxed at 85 °C for 10 h. After the reactionfinished, the mixture was poured into ice water slowly and thensaturate NaOH solution was added to adjust the pH value to 8.0under vigorous stirring. The mixture was extracted with ethyl acetatethree times, the organic layer was washed with brine anddried over anhydrous sodium sulfate. After solvent evaporation, thecrude product was purified by recrystallization from anhydrousethanol to get 3.15 g white powder, yield: 76.09percent. Melting point:188.1-189.5 °C. FT-IR (KBr, Disc, cm1): 3409.28 (m, ν NH2), 3377.72(m,ν NH2), 3304.97 (w), 3105.35 (m), 1647.15 (m), 1608.48 (m, ν CN),1578.80 (w), 1511.49 (s, ν benzene), 1465.51(s), 1304.97 (w), 1267.34(w), 1246.65 (s, ν OCH3), 1174.54 (m, ν OCH3), 1128.97 (w), 1052.67 (w),1031.98 (m), 978.88 (w), 829.22 (m), 658.86 (w), 520.48 (w). 1HNMR (DMSO-d6, 400 MHz, ppm) δ: 7.69-7.67 (d, J= 8.0 Hz, 2H),7.28 (s, 2H, NH2), 7.03-7.01 (d, J =8.0 Hz, 2H), 3.80 (s, 3H, OCH3). 13CNMR (100 MHz, DMSO) δ 167.85, 160.24, 156.25, 127.77, 123.61,144.46, 55.27. MS (ESI) m/z: found, [M+H]+, 208.0542; molecularformula C9H9N3OS requires [M+H]+, 208.0544. |
65% | Stage #1: for 5 h; Reflux Stage #2: for 7 h; Cooling; Reflux |
General procedure: A mixture ofappropriate 4-n-alkoxybenzoic acid (10 mmol) and (0.91 g, 10 mmol) of thiosemicarbazidewith 5 mL of phosphorus oxychloride was refluxed gently for 5 hr. After cooling 50 mL of water was added, the mixture was then refluxed for 7 hr and filtered, neutralizedwith potassium hydroxide. The precipitate was washed with water and recrystallized fromethanol-water to give titled compound [III]n. |
[ 247109-15-5 ]
5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.99
[ 383130-78-7 ]
5-(4-Ethylphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.82
[ 26907-54-0 ]
5-(p-Tolyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.82
[ 76074-47-0 ]
5-(m-tolyl)-1,3,4-Thiadiazol-2-amine
Similarity: 0.82
[ 100987-04-0 ]
5-(4-(tert-Butyl)phenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.81
[ 247109-15-5 ]
5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.99
[ 701227-09-0 ]
2-Methoxy-N-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)benzamide
Similarity: 0.69
[ 914348-82-6 ]
2-(4-Methoxyphenyl)thiazole-5-carbaldehyde
Similarity: 0.52
[ 15884-86-3 ]
5-(Methoxymethyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.51
[ 101078-51-7 ]
6-Methoxy-2-(p-tolyl)benzo[d]thiazole
Similarity: 0.50
[ 247109-15-5 ]
5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.99
[ 383130-78-7 ]
5-(4-Ethylphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.82
[ 26907-54-0 ]
5-(p-Tolyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.82
[ 76074-47-0 ]
5-(m-tolyl)-1,3,4-Thiadiazol-2-amine
Similarity: 0.82
[ 100987-04-0 ]
5-(4-(tert-Butyl)phenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.81
[ 247109-15-5 ]
5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.99
[ 383130-78-7 ]
5-(4-Ethylphenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.82
[ 26907-54-0 ]
5-(p-Tolyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.82
[ 76074-47-0 ]
5-(m-tolyl)-1,3,4-Thiadiazol-2-amine
Similarity: 0.82
[ 100987-04-0 ]
5-(4-(tert-Butyl)phenyl)-1,3,4-thiadiazol-2-amine
Similarity: 0.81